Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition

  title={Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition},
  author={Bernd Groner and Viktoria von Manstein},
  journal={Molecular and Cellular Endocrinology},

JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies

A better understanding of the functionally redundant roles of JAKs and STATs may provide a rationale for improving existing cancer therapies which have deleterious effects on normal cells and to identifying novel targets for therapeutic intervention in solid malignancies.

JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression

Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling mediates almost all immune regulatory processes, including those that are involved in tumor cell recognition and

Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review

Insight is provided into the JAK2/STAT3 pathway in the hope of gaining an understanding of its potential role in the pathogenesis, progression, chemotherapy resistance, and cancer therapy of solid tumors.

Blocking the JAK2/STAT3 and ERK pathways suppresses the proliferation of gastrointestinal cancers by inducing apoptosis.

Novel crosstalk between JAK2/STAT3 and ERK signaling in gastric cancer and pancreatic ductal adenocarcinoma cells is suggested and provides a therapeutic strategy to overcome potential resistance in gastrointestinal cancer.

Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers

This review will summarize the essentials of the JAK/STAT and TNF signaling pathways and their regulation and the molecular mechanisms that lead to the dysregulation of theJAK-STAT pathway and highlight the development and future of therapeutic applications which modulate the Jak-STAT or the TNF pathway in cancers.

SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.

The results confirmed that SP2509 inhibits tumor progression by suppressing the expression of JAK/STAT3 signaling and STAT3-related downstream genes and inhibited tumor growth in vivo and induces cell death in vitro.

Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map

The tumour-modulating activities of STAT3 are reviewed in light of its role as a signalling node integrating inflammatory responses during wound healing, and how excessive signal transducer and activator of transcription 3 (STAT3) activation within cancer cells and cells of the tumour microenvironment can be viewed as a neoplastic mimic of an inflammation-driven repair response that promotes tumour progression.

Proteomimetics of Natural Regulators of JAK–STAT Pathway: Novel Therapeutic Perspectives

The possibilities to target JAK–STAT by focusing on its natural inhibitors as the suppressor of cytokine signaling (SOCS) proteins are reviewed.



Multiple regulation pathways and pivotal biological functions of STAT3 in cancer

An improved understanding of the complex roles of STAT3 in cancer is required to achieve optimal therapeutic effects and no effective therapeutic inventions are available for inhibiting STAT3 and acquiring potent antitumor effects in the clinic.

The role of STAT3 signaling in mediating tumor resistance to cancer therapy.

This review will focus on STAT3 mediated resistance to cancer therapy and discuss strategies to overcome this resistance.

The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer

The promise of STAT3 as a therapeutic target to prevent prostate cancer progression and the variety ofSTAT3 inhibitors used in cancer therapies is discussed.

STAT3 Activity and Function in Cancer: Modulation by STAT5 and miR-146b

Understanding the subtleties of STAT3 signaling in cancer pathogenesis will allow the development of more rational molecular approaches to cancer therapy, and will gain greater insight into the consequence ofSTAT3 activation in the biology of human cancers.

Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt–β-catenin–mediated intestinal tumor growth and regeneration

Partial suppression of the inflammatory gp130-Jak-Stat pathway inhibits intestinal tumor growth. A Novel Strategy for Treating Colon Cancer In most patients, colon cancer arises from a mutation in

Revisiting STAT3 signalling in cancer: new and unexpected biological functions

Well known for its role in tumour cell proliferation, survival, invasion and immunosuppression, JAK–STAT3 signalling also promotes cancer through inflammation, obesity, stem cells and the pre-metastatic niche.

STAT3 the oncogene – still eluding therapy?

The role of STAT3 in tumorigenesis is focused on, and its potential as a therapeutic target for cancer treatment is discussed, as well as attempts to develop an effective STAT3 inhibitor.

The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis.

This study provides the first evidence for IL-6 expression at the leading edge of invasive human breast tumors and demonstrates mechanistically that IL- 6/JAK/Stat3 signaling plays a critical and pharmacologically targetable role in orchestrating the composition of the tumor microenvironment that promotes growth, invasion, and metastasis.

Genetic Interactions of STAT3 and Anticancer Drug Development

  • B. Fang
  • Biology, Chemistry
  • 2014
This review focuses on functional regulation ofSTAT3 activity; possible interactions of the STAT3, RAS, epidermal growth factor receptor, and reduction-oxidation pathways; and molecular mechanisms that modulate therapeutic efficacies of STAT3 inhibitors.